Advertisement
Singapore markets closed

  • Straits Times Index

    3,293.13
    +20.41 (+0.62%)
     

  • S&P 500

    5,061.09
    -9.46 (-0.19%)
     

  • Dow

    38,365.66
    -138.03 (-0.36%)
     

  • Nasdaq

    15,712.14
    +15.50 (+0.10%)
     

  • Bitcoin USD

    64,826.58
    -1,923.32 (-2.88%)
     

  • CMC Crypto 200

    1,407.34
    -16.76 (-1.18%)
     

  • FTSE 100

    8,037.25
    -7.56 (-0.09%)
     

  • Gold

    2,346.10
    +4.00 (+0.17%)
     

  • Crude Oil

    82.82
    -0.54 (-0.65%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • Nikkei

    38,460.08
    +907.92 (+2.42%)
     

  • Hang Seng

    17,201.27
    +372.34 (+2.21%)
     

  • FTSE Bursa Malaysia

    1,571.48
    +9.84 (+0.63%)
     

  • Jakarta Composite Index

    7,174.53
    +63.72 (+0.90%)
     

  • PSE Index

    6,572.75
    +65.95 (+1.01%)
     

Was This Acquisition a Savvy Play by This Big Pharma Stock?

Kody Kester, The Motley Fool
·3-min read
Was This Acquisition a Savvy Play by This Big Pharma Stock?

Earlier this month, U.K.-based drugmaker GSK (NYSE: GSK) reached a deal to buy Canadian biotech company Bellus Health (NASDAQ: BLU) for $2 billion in cash. Should GSK's deal for Bellus Health be approved by regulatory authorities and a two-thirds majority of the latter's shareholders, the former will pick up a promising drug candidate, camlipixant, that aims to treat refractory chronic cough (RCC). Surprisingly, there are no approved therapies for RCC in the United States or the European Union.

Continue reading